Reports Q4 revenue $658,000, consensus $3.14M. “We are diligently executing on our clinical programs while we strive to broaden the type and number of patients who may benefit from our novel product candidates,” said Mark Manfredi, Ph.D., Chief Executive Officer of Ikena. “Backed by our strong financial position, this year we are poised to seamlessly deliver on our developmental goals in the clinic, while also building value for our shareholders.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on IKNA:
- Ikena Oncology Reports Fourth Quarter and Full Year 2023 Financial Results
- Ikena Oncology, Inc. (IKNA) Q4 Earnings Cheat Sheet
- Ikena Oncology to Participate in TD Cowen 44th Annual Health Care Conference
- iKena Oncology CMO Sergio Santillana resigns, Caroline Germa succeeds
- Ikena Oncology Announces Leadership Change and Strategic Shift
